A Study to Evaluate the Degree of Steatosis in Subjects with any Feature of the Metabolic Syndrome in Primary Care or Endocrine Clinics for Non-Alcoholic Fatty Liver Disease (NAFLD) Utilizing Vibration Controlled Transient Elastography (VCTE) and Controll | NYU Langone Health

A Study to Evaluate the Degree of Steatosis in Subjects with any Feature of the Metabolic Syndrome in Primary Care or Endocrine Clinics for Non-Alcoholic Fatty Liver Disease (NAFLD) Utilizing Vibration Controlled Transient Elastography (VCTE) and Controll

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Non-alcoholic Fatty Liver Disease
Age: Between 18 years - 110 years
Gender: Male or Female

Other Inclusion Criteria:
1. Participants must obtain medical clearance by their primary care physician
2. Participants and/or legally authorized representative must provide signed informed consent
3. Clinical diagnosis of NAFLD based upon lab tests and medical history:
  - Liver biopsy and/or
  - Fatty Liver on imaging and/or
  - kPA of 7.0 or greater or CAP score >240 dB/m on VCTE and/or
  - Patient has Type 2 Diabetes and/or
  - BMI > 30 (obese)

You may not be eligible for this study if the following are true:

1. Consumption of >21 standard drinks per week for men and >14 standard drinks per week for women
2. Pregnant females
3. Medications that can cause liver steatosis: amiodarone, methotrexate, tamoxifen, and corticosteroids
4. Other causes of liver disease including:
  - Evidence of chronic viral hepatitis with SVR <1 year
  - Biliary obstruction
  - Hepatocellular carcinoma
  - Wilson disease
  - Budd Chiari Syndrome
  - Alcoholic liver disease
5. History of or active non-liver malignancies other than curative treated skin cancer
6. AST >300 U/L or ALT >300 U/L
7. Significant systemic or major illnesses other than liver disease that, in the opinion of the investigator, would preclude or interfere with treatment and/or adequate follow up
8. Previous liver transplantation
9. Implanted electronic medical devices (i.e.: pacemaker)